Special Issue

Structural and Other Proteomics Approaches in Drug Discovery

Message from the Guest Editors

Proteins are the primary biological targets for numerous drugs. As such, the relevance of high-throughput structural proteomics and other proteomics-related approaches in the drug discovery is easily comprehensible at different levels including target identification, target validation, potential drug toxicity and protein-protein or protein-ligand interactions. In addition to the classic experimental proteomics techniques (*e.g.*, mass spectrometry), the emergence of new *in silico* methods (*e.g.*, bioinformatics and computational modelling) as well as artificial intelligence (AI) tools can provide valuable insights to improve the current knowledge and contribute to the design of new useful drugs. In this sense, the present Special Issue entitled "Structural and other Proteomics Approaches in Drug Discovery" aims to collect reviews that consider the current state of the art and future prospects in this field, as well as original research articles reflecting. We are looking forward to receiving your valuable contributions.

Guest Editors

Dr. Marino F. A. Santos

1. Associate Laboratory i4HB - Institute for Health and Bioeconomy, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal
2. UCIBIO – Applied Molecular Biosciences Unit, Chemistry Department, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal

Dr. Luís Passarinha

1. Associate Laboratory i4HB—Institute for Health and Bioeconomy, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal
2. UCIBIO—Applied Molecular Biosciences Unit, Chemistry Department, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
3. RISE-Health, Department of Medical Sciences, Health Science Faculty, University of Beira Interior, 6201-506 Covilhã, Portugal

Deadline for manuscript submissions

closed (25 February 2025)

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/153402

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/pharmaceuticals

About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.
We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

MDPI